In a preclinical model of HCC, blocking CCL2/CCR2 signaling with a CCR2 antagonist reduced Ly6Chi monocyte numbers in the peripheral blood and suppressed anti-inflammatory macrophage polarization in the liver, ultimately inhibiting tumor growth (100). This evidence concerns the gene CCL2 and hepatocellular carcinoma.